ArticleBMC health services research2026
Cost-utility analysis of retinopathy of prematurity screening strategies of universal referral, RetCam telemedicine, and direct examination in Iran: a markov model approach.
Article in BMC health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRetinopathy of prematurity (ROP) is a leading cause of preventable childhood blindness, particularly in low- and middle-income countries. In Iran, where the prevalence of ROP among premature infants exceeds 20%, limited access to subspecialist ophthalmologists constrains timely screening. This study evaluated the cost-utility of three alternative ROP screening strategies to inform national policy on optimizing resource allocation.
methodsA lifetime, societal-perspective cost-utility analysis was conducted using a state-transition Markov model. Three strategies were compared: (1) universal referral of all at-risk infants to tertiary centers; (2) RetCam-based nurse-led imaging with remote ophthalmologist review (telemedicine); and (3) local screening by general ophthalmologists with selective referral. Model inputs were derived from national data, published literature, and expert opinion. Costs (2025 Iranian Tomans) and quality-adjusted life years (QALYs) were discounted at 5.8%. Deterministic and probabilistic sensitivity analyses were performed to assess parameter uncertainty.
resultsThe Direct Examination scenario (general ophthalmologist screening) had the lowest mean cost (33.52 USD) and effectiveness (16.83 QALYs). RetCam imaging achieved higher effectiveness (17.14 QALYs) at a cost of 122.69 USD, yielding an incremental cost-effectiveness ratio (ICER) of 288.81 USD per QALY gained, well below Iran's willingness-to-pay (WTP) threshold of USD 7,047. The Universal Referral strategy was dominated, being both more costly and less effective. Probabilistic sensitivity analysis confirmed that RetCam imaging was cost-effective in 95.2% of 10,000 Monte Carlo simulations at a WTP of USD 6,000 per QALY. Diagnostic specificity and long-term vision care costs were the key ICER drivers.
conclusionsRetCam-based telemedicine screening for ROP in Iran is highly cost-effective compared to traditional direct examination or universal referral, offering substantial long-term health gains at an acceptable cost. Scaling up telemedicine screening, supported by quality assurance and training programs, could reduce preventable childhood blindness and improve efficiency of neonatal eye care delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.